{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:55:42Z","timestamp":1784303742410,"version":"3.55.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02278-1","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T19:02:15Z","timestamp":1705086135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels"],"prefix":"10.1007","volume":"41","author":[{"given":"Manvi","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-6086","authenticated-orcid":false,"given":"Malkhey","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"1","key":"2278_CR1","first-page":"38","volume":"18","author":"TR Randolph","year":"2005","unstructured":"Randolph TR. Chronic myelocytic leukemia\u2013part I: history, clinical presentation, and molecular biology. A S C L S. 2005;18(1):38\u201348.","journal-title":"A S C L S"},{"key":"2278_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-016-0108-0","volume":"35","author":"ZJ Kang","year":"2016","unstructured":"Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, Liu B, Feng JX, Pan YJ, Yan JS, Liu Q. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35:1\u20135. https:\/\/doi.org\/10.1186\/s40880-016-0108-0.","journal-title":"Chin J Cancer"},{"key":"2278_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01150-x","volume":"14","author":"G Jiang","year":"2021","unstructured":"Jiang G, Huang Z, Yuan Y, Tao K, Feng W. Intracellular delivery of anti-BCR\/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells. J Hematol Oncol. 2021;14:1\u20138. https:\/\/doi.org\/10.1186\/s13045-021-01150-x.","journal-title":"J Hematol Oncol"},{"key":"2278_CR4","doi-asserted-by":"publisher","first-page":"117693512210763","DOI":"10.1177\/11769351221076360","volume":"21","author":"Z Zhang","year":"2022","unstructured":"Zhang Z. Lift the veil of breast cancers using 4 or fewer critical genes. Cancer Inform. 2022;21:11769351221076360. https:\/\/doi.org\/10.1177\/11769351221076360.","journal-title":"Cancer Inform"},{"key":"2278_CR5","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.neo.2022.100817","volume":"32","author":"E Kim","year":"2022","unstructured":"Kim E, Hwang EJ, Lee J, Kim DY, Kim JY, Kim DW. Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia. Neoplasia. 2022;32:100817. https:\/\/doi.org\/10.1016\/j.neo.2022.100817.","journal-title":"Neoplasia"},{"issue":"19","key":"2278_CR6","doi-asserted-by":"publisher","first-page":"10216","DOI":"10.3390\/ijms221910216","volume":"22","author":"JR Martins","year":"2021","unstructured":"Martins JR, Moraes LN, Cury SS, Capannacci J, Carvalho RF, Nogueira CR, Hokama NK, Hokama PO. MiR-125a-3p and MiR-320b differentially expressed in patients with chronic myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation and imatinib mesylate. Int J Mol Sci. 2021;22(19):10216. https:\/\/doi.org\/10.3390\/ijms221910216.","journal-title":"Int J Mol Sci"},{"key":"2278_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11899-019-00548-2","volume":"14","author":"RE Clark","year":"2019","unstructured":"Clark RE. Tyrosine kinase inhibitor therapy discontinuation for patients with chronic myeloid leukaemia in clinical practice. Curr Hematol Malig Rep. 2019;14:507\u201314. https:\/\/doi.org\/10.1007\/s11899-019-00548-2.","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"2278_CR8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u201342. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006.","journal-title":"Cancer Cell"},{"issue":"12","key":"2278_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s12032-022-01821-w","volume":"39","author":"Y Liang","year":"2022","unstructured":"Liang Y, Qin Y, Jiang G, Feng W, Yuan Y. Targeting MDC1 promotes apoptosis and sensitizes Imatinib resistance in CML cells by mainly disrupting non-homologous end-joining repair. Med Oncol. 2022;39(12):226. https:\/\/doi.org\/10.1007\/s12032-022-01821-w.","journal-title":"Med Oncol"},{"issue":"11","key":"2278_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/curroncol29110645","volume":"29","author":"X Zhang","year":"2022","unstructured":"Zhang X, Sun H, Su Y, Yi H. Long-term molecular remission after treatment with imatinib in a chronic myeloid leukemia patient with extreme thrombocytosis harboring rare e14a3 (b3a3) BCR: ABL1 transcript: a case report. Curr Oncol. 2022;29(11):45\u201352. https:\/\/doi.org\/10.3390\/curroncol29110645.","journal-title":"Curr Oncol"},{"issue":"4","key":"2278_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/10245332.2016.1252020","volume":"22","author":"I Soltani","year":"2017","unstructured":"Soltani I, Douzi K, Gharbi H, Benhassine I, Teber M, Amouri H, Ben Hadj Othman H, Farrah A, Ben Lakhel R, Abbes S, Menif S. Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance. Hematology. 2017;22(4):201\u20137. https:\/\/doi.org\/10.1080\/10245332.2016.1252020.","journal-title":"Hematology."},{"key":"2278_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fonc.2019.00939","volume":"9","author":"F Loscocco","year":"2019","unstructured":"Loscocco F, Visani G, Galimberti S, Curti A, Isidori A. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol. 2019;9:939. https:\/\/doi.org\/10.3389\/fonc.2019.00939.","journal-title":"Front Oncol"},{"issue":"4","key":"2278_CR13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/ijms21041177","volume":"21","author":"HD Popp","year":"2020","unstructured":"Popp HD, Kohl V, Naumann N, Flach J, Brendel S, Kleiner H, Weiss C, Seifarth W, Saussele S, Hofmann WK, Fabarius A. DNA damage and DNA damage response in chronic myeloid leukemia. Int J Mol Sci. 2020;21(4):1177. https:\/\/doi.org\/10.3390\/ijms21041177.","journal-title":"Int J Mol Sci"},{"key":"2278_CR14","doi-asserted-by":"publisher","first-page":"801779","DOI":"10.3389\/fonc.2021.801779","volume":"11","author":"E Andretta","year":"2021","unstructured":"Andretta E, Costa C, Longobardi C, Damiano S, Giordano A, Pagnini F, Montagnaro S, Quintiliani M, Lauritano C, Ciarcia R. Potential approaches versus approved or developing chronic myeloid leukemia therapy. Front Oncol. 2021;11:801779. https:\/\/doi.org\/10.3389\/fonc.2021.801779.","journal-title":"Front Oncol"},{"issue":"5","key":"2278_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","volume":"130","author":"G Cheloni","year":"2017","unstructured":"Cheloni G, Tanturli M, Tusa I, Ho DeSouza N, Shan Y, Gozzini A, Mazurier F, Rovida E, Li S, Dello Sbarba P. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood, J Am Soc Hematol. 2017;130(5):655\u201365. https:\/\/doi.org\/10.1182\/blood-2016-10-745588.","journal-title":"Blood, J Am Soc Hematol"},{"issue":"9","key":"2278_CR16","doi-asserted-by":"publisher","first-page":"e851","DOI":"10.1002\/mgg3.851","volume":"7","author":"H Li","year":"2019","unstructured":"Li H, Liu L, Zhuang J, Liu C, Zhou C, Yang J, Gao C, Liu G, Sun C. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis. Mol Genet Genom Med. 2019;7(9):e851. https:\/\/doi.org\/10.1002\/mgg3.851.","journal-title":"Mol Genet Genom Med"},{"issue":"3","key":"2278_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/sctm.17-0175","volume":"7","author":"E Arrigoni","year":"2018","unstructured":"Arrigoni E, Del Re M, Galimberti S, Restante G, Rofi E, Crucitta S, Barat\u00e8 C, Petrini M, Danesi R, Di Paolo A. Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment. Stem Cells Transl Med. 2018;7(3):305\u201314. https:\/\/doi.org\/10.1002\/sctm.17-0175.","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"2278_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440\u201353. https:\/\/doi.org\/10.1038\/s41375-020-01111-2.","journal-title":"Leukemia"},{"issue":"5","key":"2278_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","volume":"35","author":"JP Radich","year":"2021","unstructured":"Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MT, Garc\u00eda-Guti\u00e9rrez JV, Conneally E, Le Coutre PD, Gattermann N, Martino B. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021;35(5):1344\u201355. https:\/\/doi.org\/10.1038\/s41375-021-01205-5.","journal-title":"Leukemia"},{"issue":"4","key":"2278_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306\u201311. https:\/\/doi.org\/10.1200\/JCO.2013.52.9123.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2278_CR21","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/s41375-020-0805-1","volume":"34","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020;34(8):2064\u201373. https:\/\/doi.org\/10.1038\/s41375-020-0805-1.","journal-title":"Leukemia"},{"issue":"3","key":"2278_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359. https:\/\/doi.org\/10.1002\/ajh.25011.","journal-title":"Am J Hematol"},{"key":"2278_CR23","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3389\/fonc.2020.01544","volume":"10","author":"JR Martins","year":"2020","unstructured":"Martins JR, Moraes LN, Cury SS, Dadalto J, Capannacci J, Carvalho RF, Nogueira CR, Hokama NK, Hokama PD. Comparison of microRNA expression profile in chronic myeloid leukemia patients newly diagnosed and treated by allogeneic hematopoietic stem cell transplantation. Front Oncol. 2020;10:1544. https:\/\/doi.org\/10.3389\/fonc.2020.01544.","journal-title":"Front Oncol"},{"issue":"4","key":"2278_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","volume":"47","author":"JM Goldman","year":"2010","unstructured":"Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010;47(4):302\u201311. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.07.001.","journal-title":"Semin Hematol"},{"issue":"7","key":"2278_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41419-019-1715-x","volume":"10","author":"T Wang","year":"2019","unstructured":"Wang T, Hao D, Yang S, Ma J, Yang W, Zhu Y, Weng M, An X, Wang X, Li Y, Wu D. miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer. Cell Death Dis. 2019;10(7):495. https:\/\/doi.org\/10.1038\/s41419-019-1715-x.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2278_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-y","volume":"75","author":"RC Lee","year":"1993","unstructured":"Lee RC, Feinbaum RL, Ambros V. The C elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843\u201354. https:\/\/doi.org\/10.1016\/0092-8674(93)90529-y.","journal-title":"Cell."},{"issue":"27","key":"2278_CR27","doi-asserted-by":"publisher","first-page":"42683","DOI":"10.18632\/oncotarget.7977","volume":"7","author":"C Chakraborty","year":"2016","unstructured":"Chakraborty C, Sharma AR, Patra BC, Bhattacharya M, Sharma G, Lee SS. MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia. Oncotarget. 2016;7(27):42683\u201397. https:\/\/doi.org\/10.18632\/oncotarget.7977.","journal-title":"Oncotarget"},{"issue":"6","key":"2278_CR28","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1080\/10428194.2016.1243676","volume":"58","author":"Z Litwi\u0144ska","year":"2017","unstructured":"Litwi\u0144ska Z, Machali\u0144ski B. miRNAs in chronic myeloid leukemia: small molecules, essential function. Leuk Lymphoma. 2017;58(6):1297\u2013305. https:\/\/doi.org\/10.1080\/10428194.2016.1243676.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2278_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1101\/gr.082701.108","volume":"19","author":"RC Friedman","year":"2009","unstructured":"Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92\u2013105. https:\/\/doi.org\/10.1101\/gr.082701.108.","journal-title":"Genome Res"},{"issue":"2","key":"2278_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrg2290","volume":"9","author":"W Filipowicz","year":"2008","unstructured":"Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102\u201314. https:\/\/doi.org\/10.1038\/nrg2290.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2278_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1750-3639.2007.00121.x","volume":"18","author":"X Liu","year":"2008","unstructured":"Liu X, Fortin K, Mourelatos Z. MicroRNAs: biogenesis and molecular functions. Brain Pathol. 2008;18(1):113\u201321. https:\/\/doi.org\/10.1111\/j.1750-3639.2007.00121.x.","journal-title":"Brain Pathol"},{"issue":"5","key":"2278_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41419-018-0390-7","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X, Li Y, Wu S. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death Dis. 2018;9(5):447. https:\/\/doi.org\/10.1038\/s41419-018-0390-7.","journal-title":"Cell Death Dis"},{"key":"2278_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/d41586-023-00478-3","volume":"615","author":"G Meister","year":"2023","unstructured":"Meister G. MicroRNA uses a gym to get fit for cuts by Dicer enzyme. Nature. 2023;615:218\u20139. https:\/\/doi.org\/10.1038\/d41586-023-00478-3.","journal-title":"Nature"},{"issue":"16","key":"2278_CR34","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1101\/gad.1444406","volume":"20","author":"JM Thomson","year":"2006","unstructured":"Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006;20(16):2202\u20137. https:\/\/doi.org\/10.1101\/gad.1444406.","journal-title":"Genes Dev"},{"issue":"5","key":"2278_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1101\/gad.1399806","volume":"20","author":"MA Valencia-Sanchez","year":"2006","unstructured":"Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515\u201324. https:\/\/doi.org\/10.1101\/gad.1399806.","journal-title":"Genes Dev"},{"issue":"6","key":"2278_CR36","doi-asserted-by":"publisher","first-page":"934","DOI":"10.4161\/rna.24641","volume":"10","author":"SA Ciafr\u00e8","year":"2013","unstructured":"Ciafr\u00e8 SA, Galardi S. microRNAs and RNA-binding proteins: a complex network of interactions and reciprocal regulations in cancer. RNA Biol. 2013;10(6):934\u201342. https:\/\/doi.org\/10.4161\/rna.24641.","journal-title":"RNA Biol"},{"issue":"6","key":"2278_CR37","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1261\/rna.1804410","volume":"16","author":"I Slezak-Prochazka","year":"2010","unstructured":"Slezak-Prochazka I, Durmus S, Kroesen BJ, van den Berg A. MicroRNAs, macrocontrol: regulation of miRNA processing. RNA. 2010;16(6):1087\u201395. https:\/\/doi.org\/10.1261\/rna.1804410.","journal-title":"RNA"},{"key":"2278_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.addr.2014.10.030","volume":"81","author":"JK Banwait","year":"2015","unstructured":"Banwait JK, Bastola DR. Contribution of bioinformatics prediction in microRNA-based cancer therapeutics. Adv Drug Deliv Rev. 2015;81:94\u2013103. https:\/\/doi.org\/10.1016\/j.addr.2014.10.030.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"2278_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.blre.2016.11.003","volume":"31","author":"Q Fernandes","year":"2017","unstructured":"Fernandes Q. MicroRNA: defining a new niche in Leukemia. Blood Rev. 2017;31(3):129\u201338. https:\/\/doi.org\/10.1016\/j.blre.2016.11.003.","journal-title":"Blood Rev"},{"issue":"1","key":"2278_CR40","doi-asserted-by":"publisher","first-page":"9666","DOI":"10.1038\/s41598-019-46132-9","volume":"9","author":"R Alves","year":"2019","unstructured":"Alves R, Gon\u00e7alves AC, Jorge J, Marques G, Lu\u00eds D, Ribeiro AB, Freitas-Tavares P, Oliveiros B, Almeida AM, Sarmento-Ribeiro AB. MicroRNA signature refine response prediction in CML. Sci Rep. 2019;9(1):9666. https:\/\/doi.org\/10.1038\/s41598-019-46132-9.","journal-title":"Sci Rep"},{"issue":"5","key":"2278_CR41","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.leukres.2005.09.001","volume":"30","author":"SH Ramkissoon","year":"2006","unstructured":"Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP Jr, Sloand EM, Kajigaya S, Young NS. Hematopoietic-specific microRNA expression in human cells. Leuk Res. 2006;30(5):643\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2005.09.001.","journal-title":"Leuk Res"},{"issue":"7043","key":"2278_CR42","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nature03702","volume":"435","author":"J Lu","year":"2005","unstructured":"Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834\u20138. https:\/\/doi.org\/10.1038\/nature03702.","journal-title":"Nature"},{"issue":"2","key":"2278_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","volume":"360","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G. Restoration of miR-424 suppresses BCR\u2013ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett. 2015;360(2):245\u201356. https:\/\/doi.org\/10.1016\/j.canlet.2015.02.031.","journal-title":"Cancer Lett"},{"issue":"8","key":"2278_CR44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nmeth.3485","volume":"12","author":"H Dweep","year":"2015","unstructured":"Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12(8):697. https:\/\/doi.org\/10.1038\/nmeth.3485.","journal-title":"Nat Methods"},{"issue":"1","key":"2278_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/15476286.2017.1391441","volume":"15","author":"HM Awan","year":"2018","unstructured":"Awan HM, Shah A, Rashid F, Wei S, Chen L, Shan G. Comparing two approaches of miR-34a target identification, biotinylated-miRNA pulldown vs miRNA overexpression. RNA Biol. 2018;15(1):55\u201361. https:\/\/doi.org\/10.1080\/15476286.2017.1391441.","journal-title":"RNA Biol"},{"issue":"10","key":"2278_CR46","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.leukres.2013.07.019","volume":"37","author":"T Shibuta","year":"2013","unstructured":"Shibuta T, Honda E, Shiotsu H, Tanaka Y, Vellasamy S, Shiratsuchi M, Umemura T. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib. Leuk Res. 2013;37(10):1278\u201386. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.019.","journal-title":"Leuk Res"},{"issue":"6","key":"2278_CR47","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","volume":"13","author":"MJ Bueno","year":"2008","unstructured":"Bueno MJ, de Castro IP, de Cedron MG, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13(6):496\u2013506. https:\/\/doi.org\/10.1016\/j.ccr.2008.04.018.","journal-title":"Cancer Cell"},{"issue":"12","key":"2278_CR48","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1111\/j.1582-4934.2011.01274.x","volume":"15","author":"CS Chim","year":"2011","unstructured":"Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med. 2011;15(12):2760\u20137. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01274.x.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2278_CR49","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.3892\/ol.2015.3663","volume":"10","author":"G Wang","year":"2015","unstructured":"Wang G, Zhao R, Zhao X, Chen XI, Wang D, Jin Y, Liu XI, Zhao CI, Zhu Y, Ren C, Li M. MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib. Oncol Lett. 2015;10(5):2835\u201341. https:\/\/doi.org\/10.3892\/ol.2015.3663.","journal-title":"Oncol Lett"},{"issue":"8","key":"2278_CR50","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.yexcr.2013.02.002","volume":"319","author":"Y Li","year":"2013","unstructured":"Li Y, Wang H, Tao K, Xiao Q, Huang Z, Zhong L, Cao W, Wen J, Feng W. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR\/ABL1 protein. Exp Cell Res. 2013;319(8):1094\u2013101. https:\/\/doi.org\/10.1016\/j.yexcr.2013.02.002.","journal-title":"Exp Cell Res"},{"key":"2278_CR51","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1038\/srep12460","volume":"5","author":"Z Xishan","year":"2015","unstructured":"Xishan Z, Ziying L, Jing D, Gang L. MicroRNA-320a acts as a tumor suppressor by targeting BCR\/ABL oncogene in chronic myeloid leukemia. Sci Rep. 2015;5:12460. https:\/\/doi.org\/10.1038\/srep12460.","journal-title":"Sci Rep"},{"issue":"5670","key":"2278_CR52","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1126\/science.1097434","volume":"304","author":"S Yekta","year":"2004","unstructured":"Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304(5670):594\u20136. https:\/\/doi.org\/10.1126\/science.1097434.","journal-title":"Science"},{"issue":"1","key":"2278_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1582-4934.2010.01219.x","volume":"15","author":"C Chen","year":"2011","unstructured":"Chen C, Zhang Y, Zhang L, Weakley SM, Yao Q. MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med. 2011;15(1):14\u201323. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01219.x.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"2278_CR54","doi-asserted-by":"publisher","first-page":"e68442","DOI":"10.1371\/journal.pone.0068442","volume":"8","author":"Y Liu","year":"2013","unstructured":"Liu Y, Zheng W, Song Y, Ma W, Yin H. Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis. PLoS ONE. 2013;8(7):e68442. https:\/\/doi.org\/10.1371\/journal.pone.0068442.","journal-title":"PLoS ONE"},{"issue":"3","key":"2278_CR55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","volume":"37","author":"Y Liu","year":"2013","unstructured":"Liu Y, Song Y, Ma W, Zheng W, Yin H. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia. Leuk Res. 2013;37(3):349\u201356. https:\/\/doi.org\/10.1016\/j.leukres.2012.12.003.","journal-title":"Leuk Res"},{"issue":"10","key":"2278_CR56","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","volume":"109","author":"L Venturini","year":"2007","unstructured":"Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109(10):4399\u2013405. https:\/\/doi.org\/10.1182\/blood-2006-09-045104.","journal-title":"Blood"},{"issue":"12","key":"2278_CR57","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","volume":"103","author":"K Srutova","year":"2018","unstructured":"Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. 2018;103(12):2016. https:\/\/doi.org\/10.3324\/haematol.2018.193086.","journal-title":"Haematologica"},{"issue":"11","key":"2278_CR58","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1021\/acsomega.1c00035","volume":"6","author":"A Suchiita","year":"2021","unstructured":"Suchiita A, Guru SA, Yadav P, Masroor M, Samadhiya A, Bhutani N, Gupta N, Gupta R, Saxena A. miR-486-5p: a prognostic biomarker for chronic myeloid leukemia. ACS Omega. 2021;6(11):7711\u20138. https:\/\/doi.org\/10.1021\/acsomega.1c00035.","journal-title":"ACS Omega"},{"issue":"1","key":"2278_CR59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ng791","volume":"30","author":"D Perrotti","year":"2002","unstructured":"Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B. BCR-ABL suppresses C\/EBP\u03b1 expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30(1):48\u201358. https:\/\/doi.org\/10.1038\/ng791.","journal-title":"Nat Genet"},{"issue":"5","key":"2278_CR60","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cell.2005.09.023","volume":"123","author":"F Fazi","year":"2005","unstructured":"Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C\/EBP\u03b1 regulates human granulopoiesis. Cell. 2005;123(5):819\u201331. https:\/\/doi.org\/10.1016\/j.cell.2005.09.023.","journal-title":"Cell"},{"issue":"5","key":"2278_CR61","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","volume":"140","author":"AM Eiring","year":"2010","unstructured":"Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140(5):652\u201365. https:\/\/doi.org\/10.1016\/j.cell.2010.01.007.","journal-title":"Cell"},{"issue":"1","key":"2278_CR62","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ijc.24782","volume":"126","author":"T Zheng","year":"2010","unstructured":"Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer. 2010;126(1):2\u201310. https:\/\/doi.org\/10.1002\/ijc.24782.","journal-title":"Int J Cancer"},{"issue":"1","key":"2278_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-016-0518-2","volume":"15","author":"CH Yeh","year":"2016","unstructured":"Yeh CH, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 2016;15(1):1\u20136. https:\/\/doi.org\/10.1186\/s12943-016-0518-2.","journal-title":"Mol Cancer"},{"issue":"2","key":"2278_CR64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjh.12364","volume":"162","author":"JE Gordon","year":"2013","unstructured":"Gordon JE, Wong JJ, Rasko JE. Micro RNA s in myeloid malignancies. Br J Haematol. 2013;162(2):162\u201376. https:\/\/doi.org\/10.1111\/bjh.12364.","journal-title":"Br J Haematol"},{"issue":"1","key":"2278_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ncrna.2020.02.001","volume":"5","author":"A Buhagiar","year":"2020","unstructured":"Buhagiar A, Borg J, Ayers D. Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions. Non-coding RNA Res. 2020;5(1):22\u20136. https:\/\/doi.org\/10.1016\/j.ncrna.2020.02.001.","journal-title":"Non-coding RNA Res"},{"issue":"12","key":"2278_CR66","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","volume":"6","author":"X Agirre","year":"2008","unstructured":"Agirre X, Jim\u00e9nez-Velasco A, San Jos\u00e9-En\u00e9riz E, Garate L, Bandr\u00e9s E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, P\u00e9rez-Roger I. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6(12):1830\u201340. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0167.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"2278_CR67","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/ijlh.12351","volume":"37","author":"P Fallah","year":"2015","unstructured":"Fallah P, Amirizadeh N, Poopak B, Toogeh G, Arefian E, Kohram F, Hosseini Rad SM, Kohram M, Teimori Naghadeh H, Soleimani M. Expression pattern of key micro RNA s in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Int J Lab Hematol. 2015;37(4):560\u20138. https:\/\/doi.org\/10.1111\/ijlh.12351.","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"2278_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-10-41","volume":"10","author":"K Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","unstructured":"Machov\u00e1 Pol\u00e1kov\u00e1 K, Lopotov\u00e1 T, Klamov\u00e1 H, Burda P, Trn\u011bn\u00fd M, Stopka T, Moravcov\u00e1 J. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011;10(1):1\u20133. https:\/\/doi.org\/10.1186\/1476-4598-10-41.","journal-title":"Mol Cancer"},{"issue":"8","key":"2278_CR69","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","volume":"95","author":"S Flamant","year":"2010","unstructured":"Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JE. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010;95(8):1325. https:\/\/doi.org\/10.3324\/haematol.2009.020636.","journal-title":"Haematologica"},{"key":"2278_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-8-69","volume":"8","author":"E San Jos\u00e9-En\u00e9riz","year":"2009","unstructured":"San Jos\u00e9-En\u00e9riz E, Rom\u00e1n-G\u00f3mez J, Jim\u00e9nez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodr\u00edguez-Otero P, Jos\u00e9 Calasanz M, Pr\u00f3sper F, Agirre X. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8:1\u20134. https:\/\/doi.org\/10.1186\/1476-4598-8-69.","journal-title":"Mol Cancer"},{"key":"2278_CR71","doi-asserted-by":"publisher","first-page":"718731","DOI":"10.3389\/fonc.2021.718731","volume":"11","author":"Z Chen","year":"2021","unstructured":"Chen Z, Xie Y, Liu D, Liu P, Li F, Zhang Z, Zhang M, Wang X, Zhang Y, Sun X, Huang Q. (2021) Downregulation of miR-142a contributes to the enhanced anti-apoptotic ability of murine chronic myelogenous leukemia cells. Front Oncol. 2021;11:718731. https:\/\/doi.org\/10.3389\/fonc.2021.718731.","journal-title":"Front Oncol"},{"issue":"1","key":"2278_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-020-00183-1","volume":"9","author":"T Kl\u00fcmper","year":"2020","unstructured":"Kl\u00fcmper T, Bruckmueller H, Diewock T, Kaehler M, Haenisch S, Pott C, Bruhn O, Cascorbi I. Expression differences of miR-142-5p between treatment-na\u00efve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. Exp Hematol Oncol. 2020;9(1):1\u20135. https:\/\/doi.org\/10.1186\/s40164-020-00183-1.","journal-title":"Exp Hematol Oncol"},{"key":"2278_CR73","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2020_190612N506","author":"LM Li","year":"2020","unstructured":"Li LM, Luo FJ, Song X. MicroRNA-370\u20133p inhibits cell proliferation and induces chronic myelogenous leukemia cell apoptosis by suppressing PDLIM1\/Wnt\/\u00df-catenin signaling. Neoplasma. 2020. https:\/\/doi.org\/10.4149\/neo_2020_190612N506.","journal-title":"Neoplasma"},{"issue":"1","key":"2278_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-11-265","volume":"11","author":"M Zhou","year":"2013","unstructured":"Zhou M, Zeng J, Wang X, Guo Q, Huang T, Shen H, Fu Y, Wang L, Jia J, Chen C. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1. J Transl Med. 2013;11(1):1\u20138. https:\/\/doi.org\/10.1186\/1479-5876-11-265.","journal-title":"J Transl Med"},{"key":"2278_CR75","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190150","author":"ZY Nie","year":"2019","unstructured":"Nie ZY, Liu XJ, Zhan Y, Liu MH, Zhang XY, Li ZY, Lu YQ, Luo JM, Yang L. miR-140-5p induces cell apoptosis and decreases Warburg effect in chronic myeloid leukemia by targeting SIX1. 2019. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20190150."},{"key":"2278_CR76","doi-asserted-by":"publisher","first-page":"848199","DOI":"10.3389\/fonc.2022.848199","volume":"12","author":"MH Elias","year":"2022","unstructured":"Elias MH, Syed Mohamad SF, Abdul Hamid N. A systematic review of candidate miRNAs, its targeted genes and pathways in chronic myeloid leukemia\u2013an integrated bioinformatical analysis. Front Oncol. 2022;12:848199. https:\/\/doi.org\/10.3389\/fonc.2022.848199.","journal-title":"Front Oncol"},{"key":"2278_CR77","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201910_19159","author":"YY Liu","year":"2019","unstructured":"Liu YY, Jiao WY, Li T, Bao YY. MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia. Eur Rev Med Pharmacol Sci. 2019. https:\/\/doi.org\/10.26355\/eurrev_201910_19159.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"2278_CR78","doi-asserted-by":"publisher","first-page":"481","DOI":"10.22038\/IJBMS.2017.8671","volume":"20","author":"H Zhao","year":"2017","unstructured":"Zhao H, Liu F, Jia R, Chang H, Li H, Miao M, Wang H, Yang Z. MiR-570 inhibits cell proliferation and glucose metabolism by targeting IRS1 and IRS2 in human chronic myelogenous leukemia. Iran J Basic Med Sci. 2017;20(5):481. https:\/\/doi.org\/10.22038\/IJBMS.2017.8671.","journal-title":"Iran J Basic Med Sci."},{"issue":"9","key":"2278_CR79","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/cgt.2014.44","volume":"21","author":"Z Xishan","year":"2014","unstructured":"Xishan Z, Xianjun L, Ziying L, Guangxin C, Gang L. The malignancy suppression role of miR-23a by targeting the BCR\/ABL oncogene in chromic myeloid leukemia. Cancer Gene Ther. 2014;21(9):397\u2013404. https:\/\/doi.org\/10.1038\/cgt.2014.44.","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"2278_CR80","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2012.339","volume":"27","author":"S Agatheeswaran","year":"2013","unstructured":"Agatheeswaran S, Singh S, Biswas S, Biswas G, Chandra Pattnayak N, Chakraborty S. BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia. Leukemia. 2013;27(7):1578\u201380. https:\/\/doi.org\/10.1038\/leu.2012.339.","journal-title":"Leukemia"},{"issue":"3","key":"2278_CR81","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/ijc.28043","volume":"133","author":"S Babashah","year":"2013","unstructured":"Babashah S, Sadeghizadeh M, Hajifathali A, Tavirani MR, Zomorod MS, Ghadiani M, Soleimani M. Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem\/progenitor cells. Int J Cancer. 2013;133(3):579\u201389. https:\/\/doi.org\/10.1002\/ijc.28043.","journal-title":"Int J Cancer"},{"issue":"10","key":"2278_CR82","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41419-021-04209-2","volume":"12","author":"YY Wu","year":"2021","unstructured":"Wu YY, Lai HF, Huang TC, Chen YG, Ye RH, Chang PY, Lai SW, Chen YC, Lee CH, Liu WN, Dai MS. Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance. Cell Death Dis. 2021;12(10):908. https:\/\/doi.org\/10.1038\/s41419-021-04209-2.","journal-title":"Cell Death Dis"},{"issue":"9","key":"2278_CR83","first-page":"4308","volume":"9","author":"D Chen","year":"2017","unstructured":"Chen D, Wu D, Shao K, Ye B, Huang J, Gao Y. MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia. Am J Transl Res. 2017;9(9):4308\u201316.","journal-title":"Am J Transl Res"},{"issue":"1","key":"2278_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-9966-30-110","volume":"30","author":"SM Gao","year":"2011","unstructured":"Gao SM, Xing CY, Chen CQ, Lin SS, Dong PH, Yu FJ. miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. J Exp Clin Cancer Res. 2011;30(1):1\u20139. https:\/\/doi.org\/10.1186\/1756-9966-30-110.","journal-title":"J Exp Clin Cancer Res"},{"key":"2278_CR85","doi-asserted-by":"publisher","first-page":"110038","DOI":"10.1016\/j.cellsig.2021.110038","volume":"84","author":"D Pan","year":"2021","unstructured":"Pan D, Yang W, Zeng Y, Li W, Wang K, Zhao L, Li J, Ye Y, Guo Q. AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p. Cell Signal. 2021;84:110038. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110038.","journal-title":"Cell Signal"},{"key":"2278_CR86","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s13577-020-00367-1","volume":"33","author":"YL Li","year":"2020","unstructured":"Li YL, Tang JM, Chen XY, Luo B, Liang GH, Qu Q, Lu ZY. MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy. Hum Cell. 2020;33:610\u20138. https:\/\/doi.org\/10.1007\/s13577-020-00367-1.","journal-title":"Hum Cell"},{"issue":"4","key":"2278_CR87","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.ygeno.2021.04.014","volume":"113","author":"I Soltani","year":"2021","unstructured":"Soltani I, Bahia W, Farrah A, Mahdhi A, Ferchichi S, Almawi WY. Potential functions of hsa-miR-155-5p and core genes in chronic myeloid leukemia and emerging role in human cancer: a joint bioinformatics analysis. Genomics. 2021;113(4):1647\u201358. https:\/\/doi.org\/10.1016\/j.ygeno.2021.04.014.","journal-title":"Genomics"},{"key":"2278_CR88","doi-asserted-by":"publisher","first-page":"748","DOI":"10.17179\/excli2021-3404","volume":"20","author":"T Mahdloo","year":"2021","unstructured":"Mahdloo T, Sahami P, Ramezani R, Jafarinia M, Goudarzi H, Babashah S. Up-regulation of miR-155 potentiates CD34+ CML stem\/progenitor cells to escape from the growth-inhibitory effects of TGF-\u00df1 and BMP signaling. EXCLI J. 2021;20:748. https:\/\/doi.org\/10.17179\/excli2021-3404.","journal-title":"EXCLI J."},{"issue":"30","key":"2278_CR89","doi-asserted-by":"publisher","first-page":"49451","DOI":"10.18632\/oncotarget.17706","volume":"8","author":"S Salati","year":"2017","unstructured":"Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, Barbieri G, Curti A. Deregulated expression of miR-29a-3p, miR-494\u20133p and miR-660\u20135p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget. 2017;8(30):49451. https:\/\/doi.org\/10.18632\/oncotarget.17706.","journal-title":"Oncotarget"},{"issue":"37","key":"2278_CR90","doi-asserted-by":"publisher","first-page":"60074","DOI":"10.18632\/oncotarget.11054","volume":"7","author":"L Zhao","year":"2016","unstructured":"Zhao L, Li Y, Song X, Zhou H, Li N, Miao Y, Jia L. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Oncotarget. 2016;7(37):60074. https:\/\/doi.org\/10.18632\/oncotarget.11054.","journal-title":"Oncotarget"},{"issue":"17","key":"2278_CR91","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa050995","volume":"353","author":"GA Calin","year":"2005","unstructured":"Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa050995.","journal-title":"N Engl J Med"},{"issue":"4","key":"2278_CR92","doi-asserted-by":"publisher","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","volume":"7","author":"O Hershkovitz Rokah","year":"2012","unstructured":"Hershkovitz Rokah O, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Shpilberg O. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 2012;7(4):e35501. https:\/\/doi.org\/10.1371\/journal.pone.0035501.","journal-title":"PLoS One"},{"issue":"12","key":"2278_CR93","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1182\/blood-2006-06-032490","volume":"109","author":"H Modi","year":"2007","unstructured":"Modi H, McDonald T, Chu S, Yee JK, Forman SJ, Bhatia R. Role of BCR\/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells Blood. J Am Soc Hematol. 2007;109(12):5411\u201321. https:\/\/doi.org\/10.1182\/blood-2006-06-032490.","journal-title":"J Am Soc Hematol"},{"key":"2278_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43042-021-00156-x","volume":"22","author":"SF Mohamad","year":"2021","unstructured":"Mohamad SF, Elias MH. Potential treatment for chronic myeloid leukemia using microRNA: in silico comparison between plants and human microRNAs in targeting BCR-ABL1 gene. Egypt J Med Hum Genet. 2021;22:1\u20138. https:\/\/doi.org\/10.1186\/s43042-021-00156-x.","journal-title":"Egypt J Med Hum Genet"},{"issue":"1","key":"2278_CR95","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3892\/mmr.2018.9636","volume":"19","author":"C Gao","year":"2019","unstructured":"Gao C, Zhou C, Zhuang J, Liu L, Wei J, Liu C, Li H, Sun C. Identification of key candidate genes and miRNA-mRNA target pairs in chronic lymphocytic leukemia by integrated bioinformatics analysis. Mol Med Rep. 2019;19(1):362\u201374. https:\/\/doi.org\/10.3892\/mmr.2018.9636.","journal-title":"Mol Med Rep"},{"issue":"2","key":"2278_CR96","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18(2):189\u2013218. https:\/\/doi.org\/10.1038\/sj.leu.2403241.","journal-title":"Leukemia"},{"issue":"3","key":"2278_CR97","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","volume":"115","author":"C Peng","year":"2010","unstructured":"Peng C, Chen Y, Yang Z, Zhang H, Osterby L, Rosmarin AG, Li S. PTEN is a tumor suppressor in CML stem cells and BCR-ABL\u2013induced leukemias in mice Blood. J Am Soc Hematol. 2010;115(3):626\u201335. https:\/\/doi.org\/10.1182\/blood-2009-06-228130.","journal-title":"J Am Soc Hematol"},{"issue":"8","key":"2278_CR98","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/leu.2010.101","volume":"24","author":"M Marega","year":"2010","unstructured":"Marega M, Piazza RG, Pirola A, Redaelli S, Mogavero A, Iacobucci I, Meneghetti I, Parma M, Pogliani EM, Gambacorti-Passerini C. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients. Leukemia. 2010;24(8):1445\u20139. https:\/\/doi.org\/10.1038\/leu.2010.101.","journal-title":"Leukemia"},{"issue":"2","key":"2278_CR99","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.18632\/oncotarget.2859","volume":"6","author":"M Zhou","year":"2015","unstructured":"Zhou M, Zeng J, Wang X, Wang X, Huang T, Fu Y, Sun T, Jia J, Chen C. Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia. Oncotarget. 2015;6(2):1249. https:\/\/doi.org\/10.18632\/oncotarget.2859.","journal-title":"Oncotarget"},{"issue":"5","key":"2278_CR100","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4161\/cc.6.5.3900","volume":"6","author":"O Ashur-Fabian","year":"2007","unstructured":"Ashur-Fabian O, Adamsky K, Trakhtenbrot L, Cohen Y, Raanani P, Hardan I, Nagler A, Rechavi G, Amariglio N. Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis. Cell Cycle. 2007;6(5):589\u201394. https:\/\/doi.org\/10.4161\/cc.6.5.3900.","journal-title":"Cell Cycle"},{"issue":"3","key":"2278_CR101","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.07.030","volume":"16","author":"L Klemm","year":"2009","unstructured":"Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009;16(3):232\u201345. https:\/\/doi.org\/10.1016\/j.ccr.2009.07.030.","journal-title":"Cancer Cell"},{"key":"2278_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-410524-9.00001-3","volume":"117","author":"P Ntziachristos","year":"2013","unstructured":"Ntziachristos P, Mullenders J, Trimarchi T, Aifantis I. Mechanisms of epigenetic regulation of leukemia onset and progression. Adv Immunol. 2013;117:1\u201338. https:\/\/doi.org\/10.1016\/B978-0-12-410524-9.00001-3.","journal-title":"Adv Immunol"},{"key":"2278_CR103","doi-asserted-by":"publisher","first-page":"654411","DOI":"10.3389\/fonc.2021.654411","volume":"11","author":"M Zhou","year":"2021","unstructured":"Zhou M, Yin X, Zheng L, Fu Y, Wang Y, Cui Z, Gao Z, Wang X, Huang T, Jia J, Chen C. miR-181d\/RBP2\/NF-\u03baB p65 feedback regulation promotes chronic myeloid leukemia blast crisis. Front Oncol. 2021;11:654411. https:\/\/doi.org\/10.3389\/fonc.2021.654411.","journal-title":"Front Oncol"},{"issue":"3","key":"2278_CR104","doi-asserted-by":"publisher","first-page":"447","DOI":"10.37990\/medr.1118392","volume":"4","author":"A Karada\u011f","year":"2022","unstructured":"Karada\u011f A. Comparison of prognostic miRNA signature in patients with acute and chronic myeloid leukemia by bioinformatic analysis. Med Rec. 2022;4(3):447\u201353. https:\/\/doi.org\/10.37990\/medr.1118392.","journal-title":"Med Rec"},{"issue":"6","key":"2278_CR105","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ddr.21266","volume":"76","author":"K Kotagama","year":"2015","unstructured":"Kotagama K, Chang Y, Mangone M. miRNAs as biomarkers in chronic myelogenous leukemia. Drug Dev Res. 2015;76(6):278\u201385. https:\/\/doi.org\/10.1002\/ddr.21266.","journal-title":"Drug Dev Res"},{"issue":"7","key":"2278_CR106","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.leukres.2011.03.029","volume":"35","author":"T Lopotov\u00e1","year":"2011","unstructured":"Lopotov\u00e1 T, Z\u00e1\u010dkov\u00e1 M, Klamov\u00e1 H, Moravcov\u00e1 J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk Res. 2011;35(7):974\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2011.03.029.","journal-title":"Leuk Res"},{"key":"2278_CR107","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1479-5876-9-197","volume":"9","author":"CS Chim","year":"2011","unstructured":"Chim CS, Wan TS, Wong KY, Fung TK, Drexler HG, Wong KF. Methylation of miR-34a, miR-34b\/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med. 2011;9:197. https:\/\/doi.org\/10.1186\/1479-5876-9-197.","journal-title":"J Transl Med"},{"issue":"9","key":"2278_CR108","doi-asserted-by":"publisher","first-page":"14233","DOI":"10.1002\/jcb.28892","volume":"120","author":"H Sharifi","year":"2019","unstructured":"Sharifi H, Jafari Najaf Abadi MH, Razi E, Mousavi N, Morovati H, Sarvizadeh M, Taghizadeh M. MicroRNAs and response to therapy in leukemia. J Cell Biochem. 2019;120(9):14233\u201346. https:\/\/doi.org\/10.1002\/jcb.28892.","journal-title":"J Cell Biochem"},{"key":"2278_CR109","doi-asserted-by":"publisher","first-page":"120437","DOI":"10.1016\/j.lfs.2022.120437","volume":"296","author":"A Navabi","year":"2022","unstructured":"Navabi A, Akbari B, Abdalsamadi M, Naseri S. The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significance. Life Sci. 2022;296:120437. https:\/\/doi.org\/10.1016\/j.lfs.2022.120437.","journal-title":"Life Sci"},{"issue":"2","key":"2278_CR110","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3892\/or.2015.4456","volume":"35","author":"C Di Stefano","year":"2016","unstructured":"Di Stefano C, Mirone G, Perna S, Marfe G. The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia. Oncol Rep. 2016;35(2):614\u201324. https:\/\/doi.org\/10.3892\/or.2015.4456.","journal-title":"Oncol Rep"},{"issue":"1","key":"2278_CR111","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/onc.2012.557","volume":"33","author":"C Xu","year":"2014","unstructured":"Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Yu L. BCR-ABL\/GATA1\/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Oncogene. 2014;33(1):44\u201354. https:\/\/doi.org\/10.1038\/onc.2012.557.","journal-title":"Oncogene."},{"issue":"3","key":"2278_CR112","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/FPC.0b013e328350012b","volume":"22","author":"E Turrini","year":"2012","unstructured":"Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics. 2012;22(3):198\u2013205. https:\/\/doi.org\/10.1097\/FPC.0b013e328350012b.","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"2278_CR113","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00432-011-1137-3","volume":"138","author":"H Bai","year":"2012","unstructured":"Bai H, Cao Z, Deng C, Zhou L, Wang C. miR-181a sensitizes resistant leukaemia HL-60\/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol. 2012;138(4):595\u2013602. https:\/\/doi.org\/10.1007\/s00432-011-1137-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2278_CR114","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.semcancer.2021.03.014","volume":"83","author":"S Peixoto da Silva","year":"2022","unstructured":"Peixoto da Silva S, Caires HR, Bergantim R, Guimar\u00e3es JE, Vasconcelos MH. miRNAs mediated drug resistance in hematological malignancies. Semin Cancer Biol. 2022;83:283\u2013302. https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.014.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"2278_CR115","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/abbs\/gmr128","volume":"44","author":"H Li","year":"2012","unstructured":"Li H, Hui L, Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562\/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin. 2012;44(3):269\u201377. https:\/\/doi.org\/10.1093\/abbs\/gmr128.","journal-title":"Acta Biochim Biophys Sin"},{"key":"2278_CR116","doi-asserted-by":"publisher","first-page":"s1082","DOI":"10.1182\/blood.V112.11.1082.1082","volume":"112","author":"KM Pol\u00e1kov\u00e1","year":"2008","unstructured":"Pol\u00e1kov\u00e1 KM, Lopotov\u00e1 T, Klamov\u00e1 H, Moravcov\u00e1 J. Differential expression of miRNAs during the course of chronic myeloid leukemia. Blood. 2008;112:s1082. https:\/\/doi.org\/10.1182\/blood.V112.11.1082.1082.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02278-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02278-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02278-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T17:26:42Z","timestamp":1706722002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02278-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":116,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["2278"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02278-1","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"8 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review article does not need ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"55"}}